Business Description
Iterum Therapeutics PLC
NAICS : 325412
SIC : 2836
ISIN : IE000TTOOBX0
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.65 | |||||
Equity-to-Asset | -0.72 | |||||
Debt-to-Equity | -1.95 | |||||
Debt-to-EBITDA | -0.81 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 50.9 | |||||
3-Year EPS without NRI Growth Rate | 44.3 | |||||
3-Year FCF Growth Rate | 55.3 | |||||
3-Year Book Growth Rate | 68.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 43.78 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.21 | |||||
9-Day RSI | 40.8 | |||||
14-Day RSI | 45.77 | |||||
6-1 Month Momentum % | 67.8 | |||||
12-1 Month Momentum % | 40.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.85 | |||||
Quick Ratio | 0.85 | |||||
Cash Ratio | 0.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -60 | |||||
Shareholder Yield % | -13.74 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -132.03 | |||||
ROIC % | -287.48 | |||||
ROC (Joel Greenblatt) % | -63387.39 | |||||
ROCE % | -432.67 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -2.02 | |||||
EV-to-Forward-EBIT | -0.53 | |||||
EV-to-EBITDA | -2.06 | |||||
EV-to-Forward-Revenue | 4.78 | |||||
EV-to-FCF | -1.61 | |||||
Earnings Yield (Greenblatt) % | -49.5 | |||||
FCF Yield % | -73.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITRM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Iterum Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.71 | ||
Beta | 3.64 | ||
Volatility % | 78.61 | ||
14-Day RSI | 45.77 | ||
14-Day ATR ($) | 0.221057 | ||
20-Day SMA ($) | 2.102 | ||
12-1 Month Momentum % | 40.23 | ||
52-Week Range ($) | 0.808 - 3.02 | ||
Shares Outstanding (Mil) | 27.52 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Iterum Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Iterum Therapeutics PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Iterum Therapeutics PLC Frequently Asked Questions
What is Iterum Therapeutics PLC(ITRM)'s stock price today?
When is next earnings date of Iterum Therapeutics PLC(ITRM)?
Does Iterum Therapeutics PLC(ITRM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |